Nuron Biotech Inks Vaccine License with Mitsubishi Tanabe
By Marie Powers
Friday, January 13, 2012
Privately held Nuron Biotech Inc. hooked a big fish for its first licensing deal. The Exton, Pa.-based company signed an agreement with Mitsubishi Tanabe Pharma Corp. (MTPC), of Osaka, Japan, to commercialize its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]) in Japan, both as a single entity and for combination product use.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.